Essential Hypertension
Conditions
Brief summary
The purpose of this study is: To evaluate the effects of NEBILET®(Nebivolol), used as monotherapy or in combination with other antihypertensive agents, in the control of BP and in the metabolic profile of patients with essential hypertension (with or without co-morbidities) after 12 weeks and 24 weeks.
Detailed description
Nebivolol, the third-generation beta-blocker with vasodilatory effect, potentiates nitric oxide by activating the synthesis of nitric oxide of vascular endothelial cells and improves the function of vascular endothelial cells by reducing oxidation stress. The efficacy of NEBILET®(Nebivolol) has been demonstrated in randomized controlled trials not only as monotherapy but also as add-on therapy with angiotensin-converting-enzyme inhibitor, angiotensin II receptor blocker, diuretic and other anti-hypertensive agents in lowering the blood pressure. Based on previous study results mentioned above, the present study aims to observe the effect of NEBILET®(Nebivolol) on controlling blood pressure and metabolic profile change in Korean patients with hypertension under routine clinical practice. In addition, this study aims to identify additional benefits of NEBILET®(Nebivolol) administration in patients with essential hypertension under various treatment environments and existing co-morbidities in Korea, expected to provide detailed information about efficacy of blood pressure control, lipid and carbohydrate metabolism of NEBILET®(Nebivolol) administration in Korean patients with essential hypertension.
Interventions
None listed
Sponsors
A.Menarini Asia-Pacific Holdings Pte Ltd
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Inclusion criteria
1. Male and female patient aged 19 and older 2. In patient diagnosed with essential hypertension, * Patients who can be first treated with NEBILET®(Nebivolol) to lower high blood pressure * In patients who are receiving other antihypertensive medications, those who can switch one of the antihypertensive agents to NEBILET®(Nebivolol) or use NEBILET®(Nebivolol) as an additional therapy (In case where one of other antihypertensive agents is switched to NEBILET®(Nebivolol), it is imperative that the dose of the previous medication should exhibit the same antihypertensive effect as NEBILET®(Nebivolol) 5 mg.) 3. Subjects who have signed the written informed consent form for their voluntary participation
Exclusion criteria
1. Patient with hypersensitivity to the NEBILET®(Nebivolol) substance 2. Patient with history of bronchospasm 3. Patient with history of bronchial asthma 4. Patient with metabolic acidosis 5. Patient with bradycardia(heart rate\< 60 bpm) 6. Patient with second and third degree atrioventricular block 7. Patient with acute heart failure, cardiogenic shock, or episodes of heart failure decompensation requiring i.v. inotropic therapy) 8. Patient with uncontrolled severe heart failure 9. Patient with hypotension (Systolic Blood Pressure \< 90mmHg) 10. Patient with severe peripheral circulatory disturbances 11. Patient with sick sinus syndrome including sino-atrial block 12. Patient with untreated pheochromocytoma 13. Patient with hepatic insufficiency 14. Patient with impaired liver function 15. Pregnant woman 16. Nursing mother 17. Patient with chronic heart failure who has severe renal insufficiency (serum creatinine ≥ 250 micro mol/L) 18. Patient with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption 19. Patient who has participated in other clinical trial within the last 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean change of the Systolic Blood Pressure and Diastolic Blood Pressure | 24 weeks | Mean change of the Systolic Blood Pressure and Diastolic Blood Pressure after 12 weeks(±2 weeks) and 24 weeks (±2 weeks) compared to Baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Controlled patient rate in targeted Systolic Blood Pressure and Diastolic Blood Pressure range | 24 weeks | Controlled patient rate in targeted Systolic Blood Pressure and Diastolic Blood Pressure range after 12 weeks (±2 weeks) and 24 weeks (±2 weeks) compared to Baseline |
| Change of glucose (HbA1c, fasting blood sugar), Na, K, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol | 24 weeks | Change of glucose (HbA1c, fasting blood sugar), Na, K, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol at 12 weeks (±2 weeks) and 24 weeks (±2 weeks) compared to Baseline |
| Changes in Heart Rate and Heart Rate Variability after treatment with NEBILET® (Nebivolol) versus baseline values in patients receiving the concomitant antihypertensive therapies. | 24 weeks | Changes in Heart Rate and Heart Rate Variability at 12 weeks (±2 weeks) and 24 weeks (±2 weeks) after treatment with NEBILET® (Nebivolol) versus baseline values in patients receiving the concomitant antihypertensive therapies. |
| Mean change of the Systolic Blood Pressure and Diastolic Blood Pressure compared to baseline depending on the treatment status and type of anti-hypertensive concomitant medication | 24 weeks | Mean change of the Systolic Blood Pressure and Diastolic Blood Pressure after 12 weeks and 24 weeks compared to baseline depending on the treatment status and type of anti-hypertensive concomitant medication |
Countries
South Korea
Outcome results
None listed